Drugmakers cotton on to value of branded generics

The lower cost of developing generics is one factor driving increased interest in the sale of  branded generics products on the part of innovative drugmakers.

The Wall Street Journal reports that the USA's Abbott Laboratories (NYSE: ABT), since spinning out its innovative drug business, has achieved strong growth focusing on the development of branded versions of generics for  emerging markets.

The WSJ notes that: “In India, branded generics accounted for about 63% of all drug sales by value in 2015,” whereas: “In China, that figure stands at 55%. In the USA, by contrast, branded generics only comprise around 11% of all drug sales.”